Drug Combination Details
| General Information of the Combination (ID: C07892) | |||||
|---|---|---|---|---|---|
| Name | Hesperidin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Discovery agent
[ICD-11: N.A.]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | The 1*106 Ehrlich ascitic tumor cells were transplanted subcutaneously in the left thigh of male albino mice for the experiment. | |||||
| Experimental
Result(s) |
The use of HES as adjuvant therapy with DOX enhanced the therapeutic efficacy and alleviate the resistance to DOX in treatment of solid tumors. | |||||
